Document is current
Any future updates will be listed below
-
Authors
Adegunsoye, Ayodeji https://orcid.org/0000-0002-7015-9610
Newton, Chad A. https://orcid.org/0000-0001-5256-9029
Oldham, Justin M.
Ley, Brett
Lee, Cathryn T. https://orcid.org/0000-0002-0963-7505
Linderholm, Angela L.
Chung, Jonathan H.
Garcia, Nicole
Zhang, Da https://orcid.org/0000-0002-2983-9796
Vij, Rekha
Guzy, Robert
Jablonski, Renea
Bag, Remzi https://orcid.org/0000-0001-8313-6015
Voogt, Rebecca S.
Ma, Shwu-Fan https://orcid.org/0000-0002-3058-9480
Sperling, Anne I.
Raghu, Ganesh
Martinez, Fernando J.
Strek, Mary E.
Wolters, Paul J. https://orcid.org/0000-0002-3108-6164
Garcia, Christine Kim
Pierce, Brandon L. https://orcid.org/0000-0002-7829-952X
Noth, Imre
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (K23HL146942, K23HL148498, K23HL138190, KL2TR001870, R01HL130796)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
- License Information
-
More Information
Article History
Received: 3 April 2022
Accepted: 6 March 2023
First Online: 17 March 2023
Competing interests
: A.A. declares speaking and advisory board fees from Genentech and Boehringer Ingelheim. C.A.N. declares consulting fees from Boehringer-Ingelheim. J.M.O. declares speaking and advisory board fees from Genentech and Boehringer Ingelheim. B.L. declares speaking fees from Genentech. P.J.W. declares personal fees from Blade therapeutics, Roche and Boehringer Ingelheim. F.J.M. declares personal fees from Copeval. I.N. declares honoraria for advisory boards with Boehringer Ingelheim, InterMune, and Anthera, speaking honoraria from GSK, and consulting fees for Immuneworks. M.E.S. declares honoraria from Genentech and editorial support from Boehringer Ingelheim. The remaining authors declare no competing interests.
